Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.10819 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Jasmijn M Westerhoff und 30 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Center Utrecht, Division of Imaging and Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Radiotherapy, Image-Guided, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, Cancer Research UK.
Abstract (Originalsprache)
Importance In 2018, the first online adaptive magnetic resonance (MR)-guided radiotherapy (MRgRT) system using a 1.5-T MR–equipped linear accelerator (1.5-T MR-Linac) was clinically introduced. This system enables online adaptive radiotherapy, in which the radiation plan is adapted to size and shape changes of targets at each treatment session based on daily MR-visualized anatomy.
Objective
To evaluate safety, tolerability, and technical feasibility of treatment with a 1.5-T MR-Linac, specifically focusing on the subset of patients treated with an online adaptive strategy (ie, the adapt-to-shape [ATS] approach). Design, Setting, and Participants This cohort study included adults with solid tumors treated with a 1.5-T MR-Linac enrolled in Multi Outcome Evaluation for Radiation Therapy Using the MR-Linac (MOMENTUM), a large prospective international study of MRgRT between February 2019 and October 2021. Included were adults with solid tumors treated with a 1.5-T MR-Linac. Data were collected in Canada, Denmark, The Netherlands, United Kingdom, and the US. Data were analyzed in August 2023. Exposure All patients underwent MRgRT using a 1.5-T MR-Linac. Radiation prescriptions were consistent with institutional standards of care. Main Outcomes and Measures Patterns of care, tolerability, and technical feasibility (ie, treatment completed as planned). Acute high-grade radiotherapy-related toxic effects (ie, grade 3 or higher toxic effects according to Common Terminology Criteria for Adverse Events version 5.0) occurring within the first 3 months after treatment delivery.
Results
In total, 1793 treatment courses (1772 patients) were included (median patient age, 69 years [range, 22-91 years]; 1384 male [77.2%]). Among 41 different treatment sites, common sites were prostate (745 [41.6%]), metastatic lymph nodes (233 [13.0%]), and brain (189 [10.5%]). ATS was used in 1050 courses (58.6%). MRgRT was completed as planned in 1720 treatment courses (95.9%). Patient withdrawal caused 5 patients (0.3%) to discontinue treatment. The incidence of radiotherapy-related grade 3 toxic effects was 1.4% (95% CI, 0.9%-2.0%) in the entire cohort and 0.4% (95% CI, 0.1%-1.0%) in the subset of patients treated with ATS. There were no radiotherapy-related grade 4 or 5 toxic effects. Conclusions and Relevance In this cohort study of patients treated on a 1.5-T MR-Linac, radiotherapy was safe and well tolerated. Online adaptation of the radiation plan at each treatment session to account for anatomic variations was associated with a low risk of acute grade 3 toxic effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University Medical Center Utrecht, Division of Imaging and Oncology, Utrecht, the Netherlands.
- Elekta AB, Stockholm, Sweden.
- Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia.
- Department of Clinical Oncology, The University of Manchester, Manchester, United Kingdom.
- The Royal Marsden NHS Foundation Trust, Radiation Oncology, London, United Kingdom.
- Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee.
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- Cancer Research UK
Zitieren
APA
Westerhoff, J. M., Daamen, L. A., Christodouleas, J. P., Blezer, E. L. A., Choudhury, A., Westley, R. L., Erickson, B. A., Fuller, C. D., Hafeez, S., van der Heide, U. A., Intven, M. P. W., Kirby, A. M., Lalondrelle, S., Minsky, B. D., Mook, S., Nowee, M. E., Marijnen, C. A. M., Orrling, K. M., Sahgal, A., …, & Hall, W. A. (2024). Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.10819
Vancouver
Westerhoff JM, Daamen LA, Christodouleas JP, Blezer ELA, Choudhury A, Westley RL, et al. Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.10819
BibTeX
@article{Westerhoff2024,
author = {Westerhoff, Jasmijn M and Daamen, Lois A and Christodouleas, John P and Blezer, Erwin L A and Choudhury, Ananya and Westley, Rosalyne L and Erickson, Beth A and Fuller, Clifton D and Hafeez, Shaista and van der Heide, Uulke A and Intven, Martijn P W and Kirby, Anna M and Lalondrelle, Susan and Minsky, Bruce D and Mook, Stella and Nowee, Marlies E and Marijnen, Corrie A M and Orrling, Kristina M and Sahgal, Arjun and Schultz, Christopher J and Faivre-Finn, Corinne and Tersteeg, Robbert J H A and Tree, Alison C and Tseng, Chia-Lin and Schytte, Tine and Silk, Dustin M and Eggert, Dave and Luzzara, Marco and van der Voort van Zyp, Jochem R N and Verkooijen, Helena M and Hall, William A},
title = {Safety and Tolerability of Online Adaptive High-Field Magnetic Resonance–Guided Radiotherapy},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.10819}
}
EUVIMED